Discover Affordable Custom NGS Panels
News Feb 12, 2015
Integrated DNA Technologies (IDT) will host an informative webinar entitled ‘Custom, Affordable Gene Panels with Superior Coverage and Uniformity’ on February 18, 2015.
Presented by Rami Zahr, NGS Product Manager at IDT, the webinar will be available at 9am and 1pm Central Standard Time and explain how to design and optimize custom target capture panels at a much lower cost as well as enhance the performance of existing panels.
Off-the-shelf probe pools or panels often do not match a researcher’s experimental needs while custom designed probe pools or panels come at a high cost.
The IDT xGen® Predesigned Gene Capture Pools and Plates are built for highly uniform and specific target capture performance and webinar attendees will learn how they can be used to design and optimize new panels, as well as enhance existing panels, cost-effectively.
Attendees will also be shown how to design their own custom plates and, by mixing probes as needed, build panels to target specific CDS, UTR, introns or intergenic regions. The webinar aims to equip researchers using NGS target capture technologies with the ability to save costs and reduce waste in their work.
Researchers Discover Mutation That Appears to Protect Against Multiple Aspects of Biological AgingNews
The first genetic mutation that appears to protect against multiple aspects of biological aging in humans has been discovered in an extended family of Old Order Amish living in the vicinity of Berne, Indiana, report Northwestern Medicine scientists.READ MORE
Defects in Cell’s ‘Waste Disposal System’ Linked to Parkinson’sNews
An international study has shed new light on the genetic factors associated with Parkinson’s disease, pointing at a group of lysosomal storage disorder genes as potential major contributors to the onset and progression of this common neurodegenerative disorder.READ MORE
Mouse Model Demonstrates Potential of New Autism DrugNews
Scientists have performed a successful test of a possible new drug in a mouse model of an autism disorder. The candidate drug, largely corrected electrical, behavioral and brain abnormalities in the mice.READ MORE